Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796949 | PMC |
| http://dx.doi.org/10.1111/ijlh.13902 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.
Bone Marrow Transplant
November 2024
Hôpital Saint-Antoine Hospital and Sorbonne University, Paris, France.
Article Synopsis
- REACH2 and REACH3 were clinical studies that compared ruxolitinib, a JAK1/JAK2 inhibitor, with the best available therapy in patients with steroid-refractory acute or chronic graft-versus-host disease (GVHD).
- Early initiation of ruxolitinib treatment within 3 days of diagnosis significantly improved treatment outcomes, leading to longer response durations and higher complete response rates compared to starting treatment later.
- Despite the occurrence of clinically relevant cytopenias (low blood cell counts), patients were able to manage these side effects and maintain effective doses of ruxolitinib, demonstrating its effectiveness over other treatments for managing GVHD.
A Case of Renal Artery Thrombosis With Concurrent Adrenal Hemorrhage in Polycythemia Vera.
Cureus
September 2024
Nephrology, University of Iowa Hospitals and Clinics, Iowa, USA.
Article Synopsis
- * Diagnosis typically involves checking for high hemoglobin levels, low erythropoietin, and the presence of a specific mutation (JAK2) to confirm the disease.
- * A case study of a 68-year-old woman with PV showed how she developed renal artery thrombosis leading to acute kidney injury, requiring careful management of anticoagulation to balance the risks of both thrombosis and bleeding.
Simultaneous portal vein thrombosis and splenic vein thrombosis in a COVID-19 patient: A case report and review of literature.
World J Clin Cases
June 2024
Department of Gastroenterology and Hepatology, Brooklyn Campus of the Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY 11209, United States.
Background: It is well-described that the coronavirus disease 2019 (COVID-19) infection is associated with an increased risk of thrombotic complications. While there have been many cases of pulmonary emboli and deep vein thrombosis in these patients, reports of COVID-19 associated portal vein thrombosis (PVT) have been uncommon. We present a unique case of concomitant PVT and splenic artery thrombosis in a COVID-19 patient.
View Article and Find Full Text PDFCombined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality.
J Am Coll Cardiol
May 2024
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. Electronic address:
Article Synopsis
- Clonal hematopoiesis (CH) is a new cardiovascular risk factor linked to acquired mutations in hematopoietic stem cells, potentially impacting patients with carotid atherosclerosis.
- A study analyzed CH in 968 patients with asymptomatic carotid atherosclerosis through deep sequencing, finding that 13.7% had clonal markers, with higher prevalence in older patients.
- Results showed that the presence of CH significantly increased the risk of cardiovascular death, especially in older individuals and those with severe carotid stenosis, highlighting the importance of CH assessment for better prognostic evaluation.
Notch1 regulates hepatic thrombopoietin production.
Blood
June 2024
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Notch signaling regulates cell-fate decisions in several developmental processes and cell functions. However, the role of Notch in hepatic thrombopoietin (TPO) production remains unclear. We noted thrombocytopenia in mice with hepatic Notch1 deficiency and so investigated TPO production and other features of platelets in these mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!